Understanding Oral Hyperglycemic Agents

Type 2 diabetes medications now span multiple oral classes with very different hypoglycemia risk, renal considerations, and ED implications. Sulfonylureas and meglitinides are the oral agents most likely to explain recurrent hypoglycemia, while metformin remains the usual first discharge choice for newly diagnosed type 2 diabetes when follow-up is uncertain.

ED Approach to Oral Diabetes Drugs

• Medication list review: Unfamiliar diabetes drugs are now common in the ED, and the fastest high-yield step is a deliberate medication reconciliation focused on agents that raise insulin versus those that do not. We lay out the practical categories in the episode.
• Hyperglycemia syndromes: HHS points to severe hyperglycemia with neurologic symptoms but no acidosis, while DKA adds an anion gap metabolic acidosis and ketonemia despite a similar glucose range.
• Discharge glucose targets: There is no evidence-based ED glucose number that guarantees safe discharge; the useful point is clinical stability, not a magic cutoff, and the threshold debate is worth hearing in the chapter.
• Common adverse effects: GI upset is the class-wide side effect you will hear about most often, so taking these medications with food is practical advice, while renal injury is less common but matters for follow-up labs.
• Metformin first choice: Metformin decreases hepatic gluconeogenesis, does not increase insulin levels, and alone does not cause hypoglycemia, making it the go-to oral start for many newly diagnosed patients headed home.

High-Risk and Lower-Risk Medication Classes

• Sulfonylurea hypoglycemia risk: Sulfonylureas are insulin secretagogues with long half-lives, so glyburide, glipizide, and glimepiride can produce recurrent hypoglycemia that outlasts an initial ED correction.
• Meglitinide comparison: Repaglinide and nateglinide are shorter-acting secretagogues dosed with meals, so they carry less prolonged hypoglycemia risk than sulfonylureas even though the mechanism is similar.
• Metformin renal caution: Metformin is generally hypoglycemia-sparing, but acute severe kidney injury raises concern for accumulation and the rare complication of lactic acidosis.
• SGLT2 urinalysis clue: SGLT2 inhibitors block renal glucose reabsorption, so marked glucosuria on urinalysis can be a medication effect rather than a diagnostic surprise; we get into the bedside implications in the podcast.
• Low hypoglycemia classes: GLP-1 agonists, DPP-4 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors have low standalone hypoglycemia risk because they do not drive sustained unregulated insulin release.

References:

1. Godfrey J, McQuillan S. Newer Diabetes Drugs: Are You a Candidate? For some people taking metformin for type 2 diabetes, adding a medication from a newer drug class can help improve outcomes. But they’re not for everyone. Health Central. March 10, 2023 https://www.endocrineweb.com/conditions/type-2-diabetes/type-2-diabetes-treatments-newer-medications
2. Illinois U of. Diabetes: New drug treatment options. Healthline. August 11, 2022. https://www.healthline.com/health/diabetes/diabetes-new-drugs
3. Khardori R. Type 2 diabetes Mellitus Medication. Medscape.  May 1, 2023. https://emedicine.medscape.com/article/117853-medication